Verona Pharma Stock (NASDAQ:VRNA), Trade Ideas

Verona Pharma

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Analyst Color

Biotech

Equities

News

Health Care

Price Target

Reiteration

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

VRNA

In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revealed the company&#39;s intent to pursue acquisitions within the $2 billion (£1.6 billion) range over the upcoming six months, aiming to fortify its pipeline.

Verona Pharma&#39;s Promising COPD Treatment Puts It in GSK&#39;s Acquisition Crosshairs, Analysts Predict Big Moves

Penny Stocks

Intraday Update

Movers

AAOI

ABSI

ADEX

ARBB

ASST

AWIN

BACK

BNZI

BTCT

CVRX

DERM

ENLV

FPAY

FUSN

GMBL

GRCL

Hollsys Automation Technologies INTERNATIONAL

HOLI

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

LDTC

MIST

NDRA

NEOV

NXTP

ONCT

PSNY

RYZB

SGHT

SNCE

SNTG

SSYS

STBX

SXTP

TURB

TUYA

VLCN

WORX

ZJYL

Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth $4.1 billion.

RayzeBio shares gained 100% to $61.38 on Tuesday.

Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

ATLX

ETNB

MARA

MLTX

RCMT

SCHW

STGW


	HC Wainwright &amp; Co. cut the price target for  89bio, Inc.  (NASDAQ: ETNB) from $27 to $25. HC Wainwright &amp; Co. analyst Ed Arce maintained a Buy rating. 89bio shares fell 5.2% to trade at $11.80 on Monday.


Charles Schwab To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Monday

Verona Pharma plc - American Depositary Shares

Verona Pharma PLC

TD Cowen analyst Matthew Ramsay maintains Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) with a Hold and lowers the price target from $42 to $35.

INTC

TD Cowen Maintains Hold on Intel, Lowers Price Target to $35

Evercore ISI Group analyst Oliver Wintermantel maintains Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) with a Outperform and raises the price target from $275 to $280.

TSCO

Evercore ISI Group Maintains Outperform on Tractor Supply, Raises Price Target to $280

AERWINS Technologies Shares Resume Trade

Evercore ISI Group maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a In-Line and lowers the price target from $15 to $14.

TDOC

Evercore ISI Group Maintains In-Line on Teladoc Health, Lowers Price Target to $14

TD Cowen analyst John Blackledge maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Buy and raises the price target from $170 to $200.

GOOG

GOOGL

TD Cowen Maintains Buy on Alphabet, Raises Price Target to $200

Evercore ISI Group analyst Mark Mahaney maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a In-Line and raises the price target from $13 to $14.

SNAP

Evercore ISI Group Maintains In-Line on Snap, Raises Price Target to $14

Evercore ISI Group analyst Eric Serotta maintains Boston Beer Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) with a In-Line and raises the price target from $310 to $325.

Evercore ISI Group Maintains In-Line on Boston Beer Co, Raises Price Target to $325

ACM Research Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>) shares are trading lower on Friday after the company announced preliminary unaudited&nbsp;<a href="https://www.benzinga.com/pressreleases/24/04/g38454367/acm-research-announces-preliminary-unaudited-revenue-and-shipments-for-the-first-quarter-2024" target="_blank" rel="noreferrer noopener">revenue and shipments for the first quarter.</a>
The company registered preliminary unaudited revenue for the first quarter of 2024 of $150 million to $152 million versus&nbsp;the estimate&nbsp;of $152.41 million.&nbsp;This&nbsp;represents&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">year-over-year growth of 102% to 105%</a>.
The company said preliminary total shipments&nbsp;are expected&nbsp;to be&nbsp;in the range of&nbsp;$235 million to $240 million,&nbsp;which would represent&nbsp;year-to-year growth of 163% to 169%.
ACM Research&nbsp;reaffirmed&nbsp;full year&nbsp;2024 revenue outlook in the range of $650 million to $725 million versus $701.7 million,&nbsp;which would&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">represent&nbsp;year-to-year growth of 17% to 30%.</a>
According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>, ACM Research stock has gained over 117% in the past year. Investors can gain exposure to the stock via Invesco Semiconductors ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSI#NYSE">PSI</a>) and Matthews China Discovery Active ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHS#NASDAQ">MCHS</a>).
ACMR Price Action:&nbsp;ACM Research shares are trading lower by 4.28% to $27.08 at publication Friday.&nbsp;
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38465570/snap-investors-celebrate-q1-earnings-but-analysts-arent-ready-to-party-just-yet-the">Snap Investors Celebrate Q1 Earnings, But Analysts Aren&#8217;t Ready To Party Just Yet: &#8216;The Most Expensive Name In Social&#8217;</a>

ACMR

MCHS

PowerShares Exchange-Traded Fund Trust Dynamic Semiconductor Portfolio

Why ACM Research Shares Are Falling Today

AERWINS Technologies Shares Halted On Circuit Breaker To The Upside, Stock Now Up 73.4%

Evercore ISI Group maintains Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) with a In-Line and lowers the price target from $28 to $27.

PDCO

Evercore ISI Group Maintains In-Line on Patterson Cos, Lowers Price Target to $27

Wedbush analyst Nick Setyan maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Outperform and raises the price target from $340 to $400.

WING

Wedbush Maintains Outperform on Wingstop, Raises Price Target to $400

Peoples Bancorp of NC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEBK#NASDAQ">PEBK</a>) reported quarterly earnings of $0.72 per share. This is a 28.57 percent increase over earnings of $0.56 per share from the same period last year. The company reported $19.34 million in sales this quarter. This is a 7.76 percent increase over sales of $17.95 million the same period last year.

Earnings

PEBK

Peoples Bancorp of NC Q1 EPS $0.72 Up From $0.56 YoY, Sales $19.34M Up From $17.95M YoY

Evercore ISI Group analyst Greg Melich maintains O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Outperform and lowers the price target from $1220 to $1200.

ORLY

Evercore ISI Group Maintains Outperform on O'Reilly Automotive, Lowers Price Target to $1200

Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares are trading higher Friday. Several AI-related and chip stocks are rising following better-than-expected earnings from Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38441148/metas-q1-earnings-analysts-say-support-its-ai-strategy-use-meta-as-a-source-of-fund">increased its capex outlook.&nbsp;</a>
The Details:
Microsoft delivered better-than-expected first-quarter results Thursday, and Microsoft CEO Satya Nadella highlighted <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38465071/microsoft-q3-shines-light-on-ai-innovation-cycle-analysts-see-plenty-of-runway-for-">strong demand </a>for the company's offerings, particularly in the field of artificial intelligence (AI).
Meta also reported strong first-quarter results this week and raised its capital expenditures outlook amid the company's increased efforts in AI.
Wedbush analyst Dan Ives expressed his <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38463199/dan-ives-says-ai-is-the-fourth-industrial-revolution-after-robust-results-from-micr">excitement </a>about the strong results from Microsoft and Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and emphasized the need for increased AI spending, as companies shift towards the "fourth industrial revolution."
Nvidia shares have gained nearly 15% over the past five days after dropping 10% last Friday in the stock's largest one-day loss since 2020.&nbsp;
Related News: <a href="https://www.benzinga.com/news/earnings/24/04/38445632/snap-shares-soar-on-better-than-expected-q1-results-daily-active-user-growth-q2-revenue-guidance">Snap Shares Soar On Better-Than-Expected Q1 Results, Daily Active User Growth, Q2 Revenue Guidance</a>
<h2 class="wp-block-heading">Should I Sell My NVDA Stock? </h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Shares of Nvidia have gained 214.76% year to date. This compares to the average annual return of 74.89%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity. 
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Nvidia stock currently has an RSI of 46.67, indicating neutral conditions.
For analysis tools, charting data and access to exclusive stock news, check out <a href='https://pro.benzinga.com/'>Benzinga PRO. Try it for free.</a> 
NVDA Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Nvidia shares are up 5.91% at $875.16 at the time of publication Friday.
Image: Shutterstock

MSFT

NVDA

What's Going On With Nvidia's Stock?

Evercore ISI Group analyst Ross Muken maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and lowers the price target from $350 to $330.

ICLR

Evercore ISI Group Maintains Outperform on Icon, Lowers Price Target to $330

WIIM

MOG/A

Moog shares are trading lower after the company reported worse-than-expected Q2 financial results and raised its FY24 guidance above estimates.

Evercore ISI Group analyst Jonathan Chappell maintains Hub Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBG#NASDAQ">HUBG</a>) with a Outperform and lowers the price target from $46 to $44.

HUBG

Evercore ISI Group Maintains Outperform on Hub Group, Lowers Price Target to $44

Phillips 66 Expects Gasoline, Diesel Demand To Remain Flat In 2024

Macro Economic Events

Econ #s

Economics

U.S. Baker Hughes Oil Rig Count -5; U.S. Baker Hughes Gas Rig Count -1; U.S. Baker Hughes Total Rig Count 613 Vs 619 Prior

Trump Media & Technology Group shares are trading higher as the stock continues to experience volatility.

Verona Pharma plc 2023 Q4 - Results - Earnings Call Presentation

Verona Pharma plc (VRNA) Q4 2023 Earnings Call Transcript

Verona Pharma (VRNA) has disclosed a new risk, in the Share Price & Shareholder Rights category. Verona Pharma faces the risk that the potential sa...

Verona Pharma's New Share Price & Shareholder Rights Risk – A Cause for Worry?

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andreas Argyrides from...

Buy Rating Affirmed: Verona Pharma's Promising Future with Ensifentrine and Expanding R&D Pipeline

Truist Financial analyst Joon Lee reiterated a Buy rating on Verona Pharma (VRNA – Research Report) today and set a price target of $17.26. The com...

Truist Financial Sticks to Their Buy Rating for Verona Pharma (VRNA)

Medical marijuana market expected to grow at 22% CAGR through 2027

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C...

Buy Rating Affirmed on Verona Pharma Ahead of Ensifentrine's Expected FDA Approval and Strong Financial Standing

In a report released yesterday, Edward Nash from Canaccord Genuity maintained a Buy rating on Verona Pharma (VRNA – Research Report), with a price ...

Strong Buy Recommendation on Verona Pharma Backed by Positive Phase III Results and Robust Commercial Strategy

Sanofi and Regeneron's Dupixent set for large gains with likely COPD approval

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Verona Pharma (VRNA – Research Report) today and set a price target of $36.00. The ...

Piper Sandler Sticks to Their Buy Rating for Verona Pharma (VRNA)

CRLBF

CRON

CVSI

JAZZ

KHRNF

MJNA

REGN

SKYE

TLRY

Press Releases

Ligand Reports Third Quarter 2023 Financial Results

Verona Pharma's President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award

Financing

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference

Management

Michael Austwick Joins Verona Pharma as Non-Executive Director

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Andrew Fisher Joins Verona Pharma as General Counsel

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update